ANTCF.US Aion Therapeutic Inc
- Market cap
- USD 1.26M
- P/E
- -
- P/B
- 4.13x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jan 2025.
Is ANTCF.US undervalued?
Graham numberThe Graham number of Aion Therapeutic Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aion Therapeutic Inc fundamental analysis
No fundamental analysis for Aion Therapeutic Inc yet.
Aion Therapeutic Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aion Therapeutic Inc
Aion Therapeutic Inc. engages in the health and wellness business in the United States. The company was formerly known as Osoyoos Cannabis Inc. and changed its name to Aion Therapeutic Inc. in August 2020. Aion Therapeutic Inc. was incorporated in 2011 and is based in Vancouver, Canada.
Full company profileAion Therapeutic Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jan 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aion Therapeutic Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 367K | 1.77M |
| Gross Profit | - | -2.00K | - | -111K | -128K | -65.3K | -17.3K | 163K | 737K |
| Operating Income | -122K | -131K | -1.70M | -997K | -2.47M | -2.33M | -842K | -1.19M | -1.37M |
| EBITDA | -122K | -131K | -1.70M | -852K | -2.47M | -2.33M | -842K | -6.07M | -1.16M |
| Net Income | -1.51M | -140K | -4.93M | -673K | -8.27M | -3.82M | -257K | -6.29M | -1.66M |
| EPS | -0.08 | 0.00 | -0.18 | -0.02 | -0.09 | -0.03 | 0.00 | -0.02 | 0.00 |
| Balance Sheet | |||||||||
| Total Assets | 19.5K | 5.71M | 4.11M | 3.34M | 1.60M | 150K | 211K | 703K | 1.21M |
| Total Liabilities | 237K | 1.55M | 1.47M | 1.20M | 1.21M | 2.56M | 2.94M | 4.57M | 5.88M |
| Shareholders' Equity | -217K | 4.17M | 2.64M | 2.13M | 397K | -2.41M | -2.73M | -3.87M | -4.67M |
| Cash & Short-term Investments | 15.9K | 5.24M | 1.62M | 613K | 240K | 336.00 | 336.00 | 68.3K | 13.8K |
| Total Debt | - | 1.45M | 1.18M | 959K | 567K | 677K | 970K | 2.08M | 2.81M |
| Cash Flow | |||||||||
| Operating Cash Flow | -118K | -333K | -1.32M | -552K | -2.13M | -1.35M | -41.4K | -845K | -983K |
| Capital Expenditure | 0.00 | 1.95M | 1.95M | 205K | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -118K | -333K | -3.27M | -756K | -3.58M | -1.35M | -41.4K | -845K | -983K |
| Ratios | |||||||||
| ROE | - | -3.4% | -187.0% | -31.5% | -2,079.5% | - | - | - | - |
| ROA | -7,738.4% | -2.5% | -120.1% | -20.2% | -515.4% | -2,543.2% | -121.8% | -894.5% | -137.7% |
| Net Profit Margin | - | - | - | - | - | - | - | -1,710.9% | -93.9% |
| Debt to Equity | - | 0.35x | 0.45x | 0.45x | 1.43x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aion Therapeutic Inc dividends
Aion Therapeutic Inc has not paid dividends in the last 8 fiscal years.
Who owns Aion Therapeutic Inc
Ownership data of Aion Therapeutic Inc is not available yet.
Aion Therapeutic Inc company profile
- Company name
- Aion Therapeutic Inc
- Ticker
- ANTCF.US
- ISIN
- CA00905T1021
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- April
- Address
- 700 West Georgia Street, Vancouver, BC, Canada, V7Y 1K8
- Phone
- 416 460 3000
- Website
- aiontherapeutic.com
About Aion Therapeutic Inc
Aion Therapeutic Inc. engages in the health and wellness business in the United States. The company was formerly known as Osoyoos Cannabis Inc. and changed its name to Aion Therapeutic Inc. in August 2020. Aion Therapeutic Inc. was incorporated in 2011 and is based in Vancouver, Canada.
Aion Therapeutic Inc management
3- Mr. John Graham Simmonds Jr.CEO, COO & Executive Vice Chair of Board · born 1974
- Mr. Rakesh Malhotra (US), B.Com., C.A., C.P.A., CA (Canada), F.C.A., FChief Financial Officer · born 1955
- Ms. Patricia PurdyCorporate Secretary · born 1947